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Pseudomonas aeruginosa is a Gram-negative bacterium and causes respiratory infection especially in elderly patients. Royal jelly
has been used worldwide as a traditional remedy and as a nutrient; however, the effect against P. aeruginosa is unclear. The aim of
this study was to analyze antibacterial, antiadherent, and anti-inflammatory effects of royal jelly against P. aeruginosa. Wild-type
strain PAO1 and clinical isolates of P. aeruginosa were used for antibacterial assay and antiadherent assay to abiotic surface and
epithelial cells, which are pharynx (Detroit 562) and lung (NCI-H292) epithelial cells. In anti-inflammatory assay, epithelial cells
were pretreated with royal jelly before bacterial exposure to investigate its inhibitory effect on interleukin (IL-8) and macrophage
inflammatory protein-3𝛼/CCL20 overproduction. Although royal jelly did not have antibacterial activity at concentration of
50%w/v, antiadherent activity was confirmed on the abiotic surface and epithelial cells under concentration of 25%. Pretreatment
with royal jelly significantly inhibited overproduction of IL-8 andCCL20 from both cells.These results demonstrated that royal jelly
inhibits P. aeruginosa adherence and protects epithelial cells from excessive inflammatory responses against P. aeruginosa infection.
Our findings suggested that royal jelly may be a useful supplement as complementary and alternative medicine for preventing
respiratory infection caused by P. aeruginosa.
1. Introduction
Pseudomonas aeruginosa is an opportunistic pathogen in
human and is a Gram-negative rod which is abundantly
found in soil, plant, decaying matter, and water. This bac-
terium is able to survive in various habitats, because it can
use various organic compounds as carbon and nitrogen
resources. Although it is classified as an obligate aerobe, this
species can grow in anaerobic environment such as in periapi-
cal lesion caused by dental infection [1, 2]. In chronic periapi-
cal lesion, P. aeruginosa was identified in mixed population
together with other species [2]. It was also one of frequent
microorganisms which survive in persistent or secondary
periapical infection and root canal tissue [3, 4]. It sometimes
causes respiratory infection especially in elderly patients. Our
previous report showed that P. aeruginosa colonized in oral
cavity could be a risk factor of aspiration pneumonia in the
elderly patients with cerebrovascular diseases and dysphagia
[5]. It has also been known that P. aeruginosa is the most
important etiological factor causing fatal nosocomial infec-
tions and found to be resistant to several antibiotics. Previous
study has reported that this pathogen was identified as the
second rank of species isolated from monomicrobial noso-
comial bloodstream infection and caused 47.9% and 27.6% of
mortality in intensive-care unit (ICU) patients and in non-
ICU patients, respectively [6]. Some isolates were resistant
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to piperacillin, ticarcillin-clavulanate (Tic-Clv), ceftazidime,
imipenem (IPM), aztreonam, ciprofloxacin (CPFX), gen-
tamycin, and tobramycin [6]. The increasing of antibiotic
resistant P. aeruginosa has become a worldwide problem.
Bacterial adherence to the surface of epithelial cells is an
initial step in bacterial colonization and induction of path-
ological responses on host tissue [7]. Virulence factor mole-
cules determine the ability of P. aeruginosa to induce patho-
logical responses. Those factors also play important roles in
bacterial colonization, survival, and their invasion into host
tissue [8].
Royal jelly is a secretion produced from the hypopha-
ryngeal and mandibular glands of young worker honeybees
and contains all the nutrients to develop the queen honeybee
from the larva. It is composed of water, carbohydrate, lipids,
proteins, vitamins (mainly riboflavin, niacin, and thiamin),
some minerals (mainly calcium and iron), and other com-
ponents and has been used worldwide as a traditional and
ethopharmacological nutrient and remedy [9]. A number of
studies demonstrated that it possesses antimicrobial activities
and antitumor and anti-inflammatory activities. However,
the effect of royal jelly against P. aeruginosa was studied only
to a limited extent and the results do not allow drawing
definitive conclusions [10–12].
We made a hypothesis that increased adherence corre-
lates to an increase in the production of proinflammatory
cytokines and the concentrations of royal jelly inhibiting
adherence are also inhibiting inflammation. Therefore, the
aim of this study was to analyze the effect of royal jelly on the
adherence of P. aeruginosa to abiotic surface and human
pharyngeal and lung epithelial cell lines, Detroit 562 and
NCI-H292, as good experimental model for in vitro P. aerug-
inosa adherence, and to examine cytotoxicity and anti-
inflammatory effects of royal jelly on these human epithelial
cells stimulated with P. aeruginosa.
2. Materials and Methods
2.1. Bacterial Strains, Growth Condition, and Antibiotics. P.
aeruginosa PAO1, wild-type strain, and four clinical isolates,
TUH-54, TUH-124, TUH-188, and TUH-213, were used in
this study. Four clinical isolates were isolated from oral cavity
or respiratory tract. IPM and CPFX were purchased from
Wako Pure Chemical Industries (Osaka, Japan). Amikacin
(AMK) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). All P. aeruginosa strains were grown at 37∘C in
lysogeny broth (LB) or on LB agar plates. For each exper-
iment, bacterial cells were picked up from single colony,
inoculated in LB broth, and incubated at 37∘C for 16 h of
shaking.
2.2. Cell Line Culture. Detroit 562 (American Type cul-
ture collection; ATCC, Manassas, VA, USA) and NCI-H292
(ATCC, Manassas, VA, USA) epithelial cell lines derived
from pharynx and lung, respectively, were used. Detroit 562
cells were cultured in minimum essential medium alpha sup-
plemented with 2mM glutamine, 1% nonessential amino
acids, 1mM sodium pyruvate, 0.1% lactalbumin hydrolysate,
10% (vol/vol) fetal bovine serum (FBS), 100 𝜇gmL−1 strepto-
mycin, and 100 units mL−1 penicillin, and NCI-H292 cells
were cultured in RPMI1640 medium supplemented with
2mM glutamine, 10% (vol/vol) FBS, 100𝜇gmL−1 strepto-
mycin, and 100 units mL−1 penicillin, in a water-saturated
atmosphere of 95% air and 5% CO
2
at 37∘C. Both cells
in medium were seeded in wells of 24-well tissue culture
plate and incubated until confluent monolayers developed.
Confluent monolayers were used in all experiments.
2.3. Royal Jelly Preparation. Royal jelly was purchased from
Yamada Bee Farm (Okayama, Japan). Royal jelly was sus-
pended in phosphate buffered saline (PBS) and stirred
overnight at 4∘C. The suspension was then centrifuged at
12,000𝑔 for 15min at 4∘C followed by filtration using 0.45𝜇m
pore filter and kept at 4∘C until just before use. For bacterial
susceptibility test, fresh working solution of royal jelly was
prepared in PBS or LB broth.
2.4. Susceptibility Assay. The minimum inhibitory concen-
trations (MICs) of antibiotics and royal jelly were assessed
by the standard microbroth dilution method. Approximately
1 × 106 cells mL−1 of bacterial culture was inoculated into
100 𝜇l of LB broth containing a twofold serial dilution of
antibiotics or royal jelly suspension in 96-well culture plate
(TPP, Trasadingen, Switzerland) and incubated for 24 h at
37∘C. The MIC was defined as the lowest concentration
showing no bacterial growth.
2.5. Bacterial Adherence Assay. Bacterial adherence assay for
abiotic surfacewas performedusing 96-well plates. Royal jelly
was added in the culturemediumbefore bacterial inoculation
at the concentration of 25%. Approximately 1 × 106 cells
mL−1 of P. aeruginosa culture was inoculated into 100𝜇l of LB
broth and then incubated for 6 h at 37∘C. After incubation,
adherent bacteria were washed with purified water twice
without disturbing the adherent bacteria and stained with
0.1% crystal violet for 10min at room temperature, and
excess stain was removed by gentle washes with purified
water twice. After being dried, stained adherent bacteria were
extracted from well by adding 150 𝜇l of ethanol and the
absorbance of the extract from stained adherent bacteria
was measured at 595 nm using a microplate reader (model
680; Bio-Rad Laboratories, Hercules, CA, USA). For dose-
dependent study, PAO1 and representative clinical isolate
TUH-54 were cultured with 5, 12.5, 20, and 25% royal jelly
suspension in culture medium.
Bacterial adherence assay for epithelial cells was also
performed. Confluent Detroit 562 and NCI-H292 cell mono-
layers were preincubated with the various concentrations
of royal jelly (12.5, 20, and 25%) for 30min at 37∘C. And
then, P. aeruginosa PAO1 or TUH-54 was directly added to
each epithelial cell in 24-well tissue culture plates at final
concentration of 1 × 108 cells mL−1 and incubated for 1 h.
As a positive control, both epithelial cells were stimulated
with bacteria without pretreatment of royal jelly. All exper-
iments were done using antibiotic-free culture medium.
P. aeruginosa adherence to royal jelly-pretreated epithelial
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Table 1: Susceptibility to antibiotics and royal jelly for P. aeruginosa.
Strain Origin MIC (𝜇g mL
−1) MIC (%)
IPM CPFX AMK Royal jelly
PAO1 Wild type 1 0.25 2 ≥50
TUH-54 Pharyngeal secretions 8 0.5 16 ≥50
TUH-122 Coughed-up sputum 2 0.5 4 ≥50
TUH-188 Oral abscess 2 0.125 4 ≥50
TUH-213 Oral abscess 2 0.125 4 ≥50
cells was quantified by determining the number of colony-
forming units (CFUs) afterwashingwith PBS twice. Adherent
bacterial cells from epithelial cells were isolated by lysis with
water prior to spreading on LB agar plates. We confirmed
that there is no effect of osmotic shock caused by pure water
on the bacterial viability (data not shown). The plates were
incubated at 37∘C for 24 h and CFU counts of adherent P.
aeruginosa were determined and adherence was expressed as
the percentage of bacteria recovered from cell lysis to those
of the initial inoculums.
2.6. Lactate Dehydrogenase (LDH) Cytotoxicity Assay. The
effect of royal jelly on cell cytotoxicity was determined using
LDH assay. Confluent Detroit 562 and NCI-H292 cell mono-
layers in 24-well plates were cultured with the various
concentrations of royal jelly (5, 12.5, 20, and 25%) for 4 h at
37∘C in a water-saturated atmosphere of 95% air and 5%CO
2
.
As a positive control, the cells were treated with 0.1% Triton
X-100 and gently shaken for 10min at room temperature. For
the cytotoxicity assay, the levels of LDH in the recovered cell
culture supernatants were determined using LDH cytotoxi-
city assay kit (Cayman Chemical, Ann Arbor, MI, USA) in
accordancewith themanufacturer’s instructions. Absorbance
was measured at 490 nm using a microplate reader (Bio-Rad
Laboratories).
2.7. Royal Jelly Protection Assay. Detroit 562 monolayers
cultured in a 24-well platewere pretreatedwith 25% royal jelly
or PBS for 30 s at room temperature, washed with PBS twice,
and irritated with 0.1% Triton X-100 for 30 sec at room
temperature. The levels of LDH in the recovered cell cul-
ture supernatants were determined using LDH cytotoxicity
assay kit and absorbance was measured at 490 nm using a
microplate reader.
2.8. Chemokine Stimulation Assay. Confluent monolayers of
Detroit 562 and NCI-H292 cells were preincubated with
various concentrations of royal jelly (5, 12.5, 20, and 25%)
in antibiotic-free culture medium for 30min at 37∘C. After
30min incubation, the cells were washed with PBS twice.
And then P. aeruginosa PAO1 or TUH-54 was directly added
to each epithelial cell in 24-well tissue culture plates at final
concentration of 2.0 × 107 cells mL−1 and incubated for
4 h. After 4 h incubations, the culture medium was collected
and stored at −20∘C until being assayed. Total RNA from
the epithelial cells was isolated with NucleoSpin RNA II
(MACHEREY-NAGEL, Duren, Germany).
2.9. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA
kits (R&D Systems, Minneapolis, MN) were used to quantify
IL-8 and CCL20 in cell culture supernatants collected after P.
aeruginosa infection.
2.10. Reverse-Transcription-Polymerase Chain Reaction (RT-
PCR). RT and PCR were performed in two steps as follows.
cDNA synthesis was performed with an RNA PCR Kit
(TaKaRa, Shiga, Japan) and specific gene transcripts were
amplified with ReddyMix PCR Mix (ABgene, Surrey, UK).
The primers and PCR conditions for amplification of IL-
8, CCL20, and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) mRNA were described previously [13]. GAPDH
was used as an internal control. PCR products were analyzed
by agarose gel electrophoresis and ethidium bromide stain-
ing.
2.11. Statistical Analysis. All experiments were conducted in
triplicate or quadruplicate and statistical analyses were per-
formed using the multifactorial one-way analysis of variance
(ANOVA) with Tukey’s Multiple Comparison test. Differ-
ences were considered significant when probability values
were less than 1% (𝑝 < 0.01).
3. Results and Discussion
3.1. Studying the Comparative Susceptibility of P. aeruginosa
to Antibiotics and Royal Jelly. The antibacterial activities of
antibiotics and royal jelly against P. aeruginosawere shown in
Table 1. According to the Clinical and Laboratory Standard
Institute guideline M100-S22 break-point, TUH-54 exhibited
resistance to IPM. Royal jelly did not exhibit antibacterial
activities (≤50%w/v) against all tested bacteria. Our results
are consistent with results reported by Boukraa stating that
four kinds of royal jelly had antimicrobial activities against
P. aeruginosa; however, the MICs were from 60 to 100% [14].
From these results, we conclude that the royal jelly may have
quite low antimicrobial activity against P. aeruginosa. Major
Royal Jelly Protein-1 (MRJP-1), which is one of components in
beehive product that is Jelleine glycoproteins, has been shown
to inhibit the growth of multidrug resistant P. aeruginosa
[15]. Regarding the potency of royal jelly, our research then
was focused on investigating antiadhesion potential and
protective function of royal jelly on host cells.
3.2.The Effect of Royal Jelly on the Attachment of P. aeruginosa.
The results of microtiter plate biofilm assay demonstrated
that 25% royal jelly almost completely inhibited the bacterial
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Figure 1: The inhibition of royal jelly to P. aeruginosa bacterial
adherence. The inhibitory effect of royal jelly to the adherence of
P. aeruginosa PAO1 and TUH-54 on abiotic surface. Data represent
the means ± SDs of 4 independent experiments. Asterisks indicate
significant differences (∗∗𝑝 < 0.001) versus control group (0% royal
jelly).
adherence in PAO1, TUH-54, TUH-124, TUH-190, andTUH-
213 (99-100% inhibition, data not shown). Furthermore, in
order to determine the effective concentration of royal jelly
to inhibit bacterial adherence, we performed dose-dependent
experiments. Figure 1 shows that royal jelly could inhibit
bacterial adherence at the concentration of 5% to both PAO1
and representative isolate, TUH-54. This inhibitory effect
was increased as higher concentration of royal jelly. These
results suggest that royal jelly has the potential to inhibit
biofilm formation of P. aeruginosa by the inhibition of initial
attachment on abiotic surface, such as medical devices. The
ability of royal jelly to inhibit the attachment of bacteria
closely related to its antibacterial components. Among the
components of royal jelly including sugar proteins and lipids,
it has been proven that glycoproteins Jelleine-I–III have
antibacterial activity against both Gram-positive and Gram-
negative bacteria [16]. P. aeruginosa virulence factor, Lectin B,
which functions as the bacterial adhesin, could be blocked by
royal jelly so that this bacterium cannot attach to the substrate
[17].
In addition to the adherence on abiotic surface, we next
examine whether the royal jelly has the ability to inhibit the
adhesion of P. aeruginosa to the epithelial cells. The bacterial
adherence assay on epithelium cells demonstrated that the
adherence of both PAO1 and the representative clinical
isolate, TUH-54, was inhibited by 30min pretreatment with
various concentrations of royal jelly (Figure 2). Figure 2(a)
shows that the adherence of PAO1 on Detroit 562 cells was
inhibited by pretreatment of royal jelly in dose-dependent
manner. The adherence of TUH-54 on the same cells was
also significantly inhibited in 20% and 25% royal jelly-treated
groups (Figure 2(b)). Furthermore, the effect of royal jelly
on the adherence of PAO1 and TUH-54 to NCI-H292 cells
showed similar results to those on Detroit 562 cell (Figures
2(c) and 2(d)).
Bacterial adhesion is an initial step in the pathogenic
mechanism of P. aeruginosa infection. Oligosaccharide-me-
diated bacterium-cell recognition and adhesion are crucial
for their colonization. Lectins play important role in glyconic
recognition pattern as adhesins.There are two soluble lectins,
Lec-A (PA-IL) and Lec-B (PA-IIL), in P. aeruginosa. These
lectins are present on bacterial outer membrane and bind to
galactose and fucose, respectively.They contribute important
role in tissue damage caused by P. aeruginosa [18–21]. Some
inventions have found the possibility of using specific lectins
inhibitor as an alternative way to control the growth of P.
aeruginosa and to reduce lung injury and as well as mortality
caused by the same case, and therefore, lectins inhibition by
specific carbohydrates proposed new perspective in therapy
of P. aeruginosa infection [21]. Previous studies have con-
firmed that LecB binds to royal jelly and its hemagglutination
activity was also inhibited by this compound [17]. Besides
LecB, there are other adheren components, such as flagella
and type IV pili, which are virulence factors and play a
role in the attachment of bacteria to lung epithelial cells
[22]. The bind between the adhesins with a membrane
receptor initiates bacterial attachment to the epithelial cells
[22]. Apart from the important role of flagella and pili,
lectins, LecA and LecB, recently become a new target in the
development of new antibacterials [23]. So far, royal jelly
is known to inhibit the activity of LecB, but its effect on
flagella and pili is still unknown. The findings from this
study showed the potential inhibitory effect of royal jelly
on adherence of P. aeruginosa to the human pharyngeal
and lung epithelial cells and provide valuable information
for the management of P. aeruginosa infections in clinical
work since bacterial adhesion and biofilm formation play
important roles in the initial bacterial infection.These results
are also supported by previous study using antiadhesion-
active components of edible seeds [24]. Siryaporn et al.
showed that virulence activated through surface attachment
required quorum sensing (QS) system (mediated by LasR)
[25]. However, after 16 h incubation with 25% royal jelly,
the expressions of lasR gene were not affected by royal jelly
using qRT-PCR, suggesting that royal jelly has no effect on
QS system (Supplemental Figure in Supplementary Material
available online at https://doi.org/10.1155/2017/3191752). The
action mechanisms of royal jelly for the inhibition of P.
aeruginosa adherence are unknown and then the study
regarding the influence of royal jelly on various adhesins of P.
aeruginosa, such as LecB, flagellin, and pili, to epithelial cells
is now under investigation.
3.3. Cytotoxicity and Protective Effect of Royal Jelly on Epithe-
lial Cells. To confirm the absence of the effect of royal jelly on
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Figure 2: The inhibitory effect of royal jelly on the adherence of PAO1 and TUH-54 on human pharyngeal and lung epithelial cells. The
inhibitory effect of royal jelly on the adherence of PAO1 (a, c) and TUH-54 (b, d) to Detroit 562 (a, b) and NCI-H292 (c, d) cells. Data
represent the means ± SDs of 4 independent experiments. Asterisks indicate significant differences (∗∗𝑝 < 0.001 and ∗𝑝 < 0.01) versus
control group (0% royal jelly).
human pharyngeal and lung epithelial cells, we measured the
level of LDH released from two epithelial cell lines, Detroit
562 cells and NCI-H292. Figure 3 shows that there are no
significant differences in released LDH activity even after
treatment with 25% royal jelly. Royal jelly is one of nutritional
supplements that are safe and widely consumed. Giving royal
jelly orally, as much as 10 g kg−1, did not cause acute cytotoxic
reactions in rats [26]. Our data also support the safety of royal
jelly to use for pharynx and lung epithelial cells.
To evaluate the effect of royal jelly for preventing cell
damage, LDH assay was performed by the addition of 0.1%
Triton X-100 after pretreatment with 25% royal jelly. As
shown in Figure 3(c), royal jelly reduced LDH release by
Triton X, suggesting that royal jelly has physically protective
effect for epithelial cells.
3.4. Royal Jelly Inhibits Overproduction of Chemokines in
Human Pharyngeal and Lung Epithelial Cells. We next inves-
tigated the preventive effects of pretreatment with royal
jelly on chemokines productions in P. aeruginosa PAO1 or
TUH-54-stimulated human pharyngeal and lung epithelial
cells. P. aeruginosa PAO1 and TUH-54 strains significantly
induced IL-8 and CCL20 productions in Detroit 562 and
NCI-H292 cells after 4 h incubation (Figures 4 and 5).
Figures 4(a) and 4(b) show that the IL-8 overproduction in
pharyngeal epithelial cells, Detroit 562, after the stimulation
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Figure 3: No cytotoxicity effect of royal jelly extract on pharyngeal, Detroit 562 (a) and lung and NCI-H292 (b), epithelial cells. As a positive
control, epithelial cells were treated with 0.1% Triton X-100 and shaken gently for 10min at room temperature. Epithelial protective effect of
royal jelly against 0.1% Triton X-100 (c). Detroit 562 monolayers cultured in a 24-well plate were pretreated with 25% royal jelly or PBS for
30 s at room temperature, washed with PBS twice, and irritated with 0.1% Triton X-100 for 30 sec at room temperature. Data represent the
means ± SDs of 3 independent experiments. Asterisks indicate significant differences (∗∗𝑝 < 0.001 and ∗𝑝 < 0.01) versus control group (0%
royal jelly).
with PAO1 and TUH-54 strains was significantly reduced by
the 30min pretreatment with royal jelly in dose-dependent
manner. Moreover, the pretreatment with 20% and 25%
royal jelly significantly inhibited IL-8 production in PAO1-
stimulatedNCI-H292 cells (Figure 4(c)) andmore than 12.5%
royal jelly significantly reduced IL-8 production in TUH-
54-stimulated NCI-H292 cells (Figure 4(d)). It is interesting
that only 30min pretreatment of epithelial cells is effective
for inhibition of IL-8 overproduction by P. aeruginosa infec-
tion.
Figure 5 also shows the inhibitory effect of 30min pre-
treatment with royal jelly on CCL20 overproduction in
human pharyngeal and lung epithelial cells after stimulation
with PAO1 or TUH-54 strain for 4 h.This inhibitory effect on
CCL20 production was similar to that on IL-8.
We finally confirmed the mRNA expression levels of
CCL20 and IL-8 in human pharyngeal and lung epithelial
cells stimulated with P. aeruginosa TUH-54 or PAO1 for 4 h
by RT-PCR. Figure 6 shows that mRNA expression level of
CCL20 in P. aeruginosa TUH-54-stimulated Detroit 562 and
NCI-H292 cells for 4 h was inhibited by 30min pretreatment
with more than 12.5% royal jelly in both epithelial cells.
Similar results were seen in the mRNA expression of IL-
8 in both epithelial cells exposed to PAO1 and TUH-54
BioMed Research International 7
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Figure 4: Inhibitory effect of royal jelly on IL-8 overproduction in human pharyngeal, Detroit 562 (a, b) and lung and NCI-H292 (c, d),
epithelial cells stimulated with P. aeruginosa PAO1 (a, c) and TUH-54 (b, d) for 4 h. Data represent the means ± SDs of 4 independent
experiments. Asterisks indicate significant differences (∗∗𝑝 < 0.001 and ∗𝑝 < 0.01) between the indicated groups.
strains (data not shown). These results are consistent and
supported by previous study showing that royal jelly has anti-
inflammatory effects to suppress LPS-induced IL-6 and CXC
chemokine ligand 10 from the periodontal ligament cell line
[27].
IL-8 is a proinflammatory cytokine that can be induced
in the event of bacterial infections and has a key role in the
recruitment and activity of neutrophils, which are considered
major contributors to the tissue damage during inflammatory
diseases [28–30].Theproduction of thismolecule is increased
in cystic fibrosismousemodel infectedwithP. aeruginosaLPS
and bacterial culture supernatant [31]. The involvement of P.
aeruginosa in the oropharyngeal infection is very important
to consider. Other studies also proved that LPS and bacterial
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Figure 5: Inhibitory effect of royal jelly on CCL20 overproduction in human pharyngeal, Detroit 562 (a, b) and lung and NCI-H292 (c,
d), epithelial cells stimulated with P. aeruginosa PAO1 (a, c) and TUH-54 (b, d) for 4 h. Data represent the means ± SDs of 4 independent
experiments. Asterisks indicate significant differences (∗∗𝑝 < 0.001) between the indicated groups.
culture supernatant induce the production of IL-8 [32] and
human bronchial epithelial cells increased the production of
IL-8 by 5 h exposure with P. aeruginosa LPS [33]. Regarding
novel mechanism involved in this induction, it has been sug-
gested that the outer membrane vesicle, which is common in
all Gram-negative bacteria, plays an important role to deliver
short RNA into host cells [33]. CCL20 has been shown to
act as a chemotactic factor that attracts strongly lymphocytes
and slightly neutrophils into inflammatory lesions [34]. This
study demonstrated that royal jelly can inhibit the increased
production of IL-8 and CCL20 by stimulation with P. aerug-
inosa and these interesting findings encourage us to clarify
this inhibitory mechanism. Collectively, our results suggest
that royal jelly can reduce the inflammatory response against
P. aeruginosa infection in pharyngeal and lung epithelial
cells and may be a useful supplement as complementary
and alternative medicine for preventing respiratory infection
caused by P. aeruginosa.
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Figure 6:The inhibitory effect of royal jelly on CCL20 mRNA expression in human pharyngeal, Detroit 562 (a) and lung and NCI-H292 (b),
epithelial cells stimulated with P. aeruginosa TUH-54 strain for 4 h.
4. Conclusions
Our results demonstrated that royal jelly can inhibit the
adherence of P. aeruginosa PAO1 and TUH-54 on abiotic sur-
face in a dose-dependent manner. In addition, we elucidated
that 30min pretreatmentwith royal jelly can inhibit the adhe-
sion of both P. aeruginosa strains in pharynx and lung and
significantly reduce the overproduction of IL-8 and CCL20
in both P. aeruginosa-stimulated epithelial cells. Royal jelly
could suppress the production of proinflammatory cytokines
by inhibiting the adherence of bacteria to epithelial cells.
Furthermore, these findings suggest that certain components
of royal jelly, when identified and studied in much more
detail, might be used as complementary medicine.
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